Upregulated SMAD3 promotes epithelial-mesenchymal transition and predicts poor prognosis in pancreatic ductal adenocarcinoma

Laboratory Investigation

Volumn 94, Issue 6, 2014, Pages 683-691

  Yamazaki, Ken ^a   Masugi, Yohei ^a   Effendi, Kathryn ^a   Tsujikawa, Hanako ^a   Hiraoka, Nobuyoshi ^b   Kitago, Minoru ^a   Shinoda, Masahiro ^a   Itano, Osamu ^a   Tanabe, Minoru ^a   Kitagawa, Yuko ^a   Sakamoto, Michiie ^a  

^a KEIO UNIVERSITY   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

epithelial mesenchymal transition; pancreatic ductal adenocarcinoma; prognosis; SMAD3; TGF

Indexed keywords

SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UVOMORULIN; VIMENTIN;

ARTICLE; CANCER PROGNOSIS; CELL INFILTRATION; CELL MOTILITY; CELL TRANSFORMATION; CONTROLLED STUDY; EPITHELIUM CELL; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MESENCHYME CELL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; UPREGULATION; XENOGRAFT;

AGED; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL NUCLEUS; CLUSTER ANALYSIS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; SMAD3 PROTEIN; UP-REGULATION;

EID: 84904156674     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2014.53     Document Type: Article

References (34)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Trede M, Schwall G, Saeger HD. Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality. Ann Surg 1990;211:447-458.
3. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 1995;221:721-731.
4. Lüttges J, Schemm S, Vogel I, et al. The grade of pancreatic ductal carcinoma is an independent prognostic factor and is superior to the immunohistochemical assessment of proliferation. J Pathol 2000;191: 154-161.
5. Masugi Y, Yamazaki K, Hibi T, et al. Solitary cell infiltration is a novel indicator of poor prognosis and epithelial-mesenchymal transition in pancreatic cancer. Hum Pathol 2010;41:1061-1068.
6. Thiery JP. Epithelial-mesenchymal transitions in tumor progression. Nat Rev Cancer 2002;2:442-454.
7. Thiery JP, Acloque H, Huang RYJ, et al. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139:871-890.
8. Thiery JP, Sleeman JP. Complex networks orchestrate epithelialmesenchymal transitions. Nat Rev Mol Cell Biol 2006;7:131-142.
9. Friess H, Yamanaka Y, Büchler M, et al. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 1993;105:1846-1856.
10. Tascilar M, Skinner HG, Rosty C, et al. The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res 2001;7:4115-4121.
11. Fink SP, Mikkola D, Willson JKV, et al. TGF-beta-induced nuclear localization of Smad2 and Smad3 in Smad4 null cancer cell lines. Oncogene 2003;22:1317-1323.
12. Blackford A, Serrano OK, Wolfgang CL, et al. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res 2009;15:4674-4679.
13. Shimamura T, Sakamoto M, Ino Y, et al. Dysadherin overexpression in pancreatic ductal adenocarcinoma reflects tumor aggressiveness: relationship to e-cadherin expression. J Clin Oncol 2003;21:659-667.
14. Yamazaki K, Takamura M, Masugi Y, et al. Adenylate cyclase-associated protein 1 overexpressed in pancreatic cancers is involved in cancer cell motility. Lab Invest 2009;89:425-432.
15. Hruban RH, Boffetta P, Hiraoka N, et al. Tumors of the pancreas. In: Bosman FT, Carneiro F, Hruban RH, et al. (eds). World Health Organization Classification of Tumors of the Digestive System, Lyon, France, 2010, pp 279-337.
16. Uchida H, Yamazaki K, Fukuma M, et al. Overexpression of leucine-rich repeat-containing G protein-coupled receptor 5 in colorectal cancer. Cancer Sci 2010;101:1731-1737.
17. Schutte M, Hruban RH, Hedrick L, et al. DPC4 gene in various tumor types. Cancer Res 1996;56:2527-2530.
18. Moore PS, Sipos B, Orlandini S, et al. Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch 2001;439:798-802.
19. Welch DR, Fabra A, Nakajima M. Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc Natl Acad Sci USA 1990;87:7678-7682.
20. Markowitz SD, Roberts AB. Tumor suppressor activity of the TGFbeta pathway in human cancers. Cytokine Growth Factor Rev 1996;7: 93-102.
21. Ellenrieder V, Hendler SF, Boeck W, et al. Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res 2001;61:4222-4228.
22. Jungert K, Buck A, Buchholz M, et al. Smad-Sp1 complexes mediate TGFbeta-induced early transcription of oncogenic Smad7 in pancreatic cancer cells. Carcinogenesis 2006;27:2392-23401.
23. Achyut BR, Yang L. Transforming growth factor-b in the gastrointestinal and hepatic tumor microenvironment. Gastroenterology 2011;141:1167-1178.
24. Wang L, Kim S, Lee JH, et al. Inactivation of SMAD4 tumor suppressor gene during gastric carcinoma progression. Clin Cancer Res 2007;13: 102-110.
25. Wilentz RE, Su GH, Dai JL, et al. Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas: a new marker of DPC4 inactivation. Am J Pathol 2000;156:37-43.
26. Giehl K, Imamichi Y, Menke A. Smad4-independent TGF-beta signaling in tumor cell migration. Cells Tissues Organs 2007;185: 123-130.
27. Levy L, Hill CS. Smad4 dependency defines two classes of transforming growth factor b (TGF-b) target genes and distinguishes TGF-b-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses. Mol Cell Biol 2005;25:8108-8125.
28. Zhao S, Venkatasubbarao K, Lazor JW, et al. Inhibition of STAT3 Tyr705 phosphorylation by Smad4 suppresses transforming growth factor b-mediated invasion and metastasis in pancreatic cancer cells. Cancer Res 2008;68:4221-4228.
29. Lu S, Lee J, Revelo M, et al. Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice. Clin Cancer Res 2007;13: 5692-5702.
30. Javle MM, Gibbs JF, Iwata KK, et al. Epithelial-mesenchymal transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resected pancreatic cancer. Ann Surg Oncol 2007;14: 3527-3533.
31. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009;9:265-273.
32. Sun C, Sun L, Jiang K, et al. NANOG promotes liver cancer cell invasion by inducing epithelial-mesenchymal transition through NODAL/SMAD3 signaling pathway. Int J Biochem Cell Biol 2013;45:1099-1108.
33. Brown S, Teo A, Pauklin S, et al. Activin/Nodal signaling controls divergent transcriptional networks in human embryonic stem cells and in endoderm progenitors. Stem Cells 2011;29:1176-1185.
34. Singh AM, Reynolds D, Cliff T, et al. Signaling network crosstalk in human pluripotent cells: a Smad2/3-regulated switch that controls the balance between self-renewal and differentiation. Cell Stem Cell 2012;10:312-326.